Abbvie's long-term debt is $62B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), ABBV shows a long-term debt of $62B. That compares with $63B in the prior-year period — down 0.8% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ABBV's long-term debt is now $62B (was $63B) — a 0.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Abbvie is outperforming or lagging.
Tracking ABBV's long-term debt over time shows whether Abbvie is scaling, shrinking, or reshaping that part of the business. The current reading is $62B That compares with $63B in the prior-year period — down 0.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Abbvie's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $62B) with ownership activity and broader fundamentals.
Abbvie's long-term debt is $62B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.